Company DescriptionTissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine in the United States and internationally. It operates through BioSurgery, Orthopaedics & Dental, and GBM-V & Cardiac divisions. The company provides dCELL technology, a soft tissue decellularisation process that removes DNA and cellular material from animal and human soft tissue to repair diseased or damaged body parts; and BioRinse technology, a natural bone filler solution for osteoinductive to stimulate and regenerate native bone growth. In addition, the company provides DermaPure, a decellularised dermal allograft for reinforcement, repair, and replacement of damaged or inadequate integumental tissue and other homologous uses of human integument; and SurgiPure XD, Decellularised porcine dermal reconstructive tissue matrix for the repair of hernias and body wall defects. Further, it offers OrthoPure XT, a scaffold to replace the damaged tissue that will re-populate with the patient's own cells; ConCelltrate 100, a verified osteoinductive bone matrix; MatrixCellect 100, a demineralised bone matrix (DBM) for orthopaedic; Matrix IQ Dermis, a human-derived dermal graft, which is decellularised to remove cellular components and preserve the biological properties that promote revascularisation, repair, and augmentation of damaged tissue; and Matrix OI FlexIt, a thin pliable demineralised cortical allograft bone sheet. Additionally, the company provides DentalFix, a mineralized particulate allograft that offer osteoconductive properties of natural bone; CardioPure products; Matrix OI 100 DBM for non-structural bone-grafting; Matrix OI Strips and Blocks, a stem cell containment human scaffold; AmnioWorks for ophthalmology and wound covering; and sports medicine products. The company was incorporated in 2006 and is based in Garforth, the United Kingdom.

How the Company Makes Money

Tissue Regenix Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Breakdown
Income Statement		Total Revenue
29.49M	19.87M	14.36M	12.83M	13.03M
	Gross Profit
14.04M	9.14M	5.63M	5.13M	4.97M
	EBIT
-394.00K	-1.61M	-2.98M	-4.12M	-7.18M
	EBITDA
446.00K	-690.87K	-2.19M	-9.03M	-6.13M
	Net Income Common Stockholders
-1.71M	-2.19M	-3.48M	-9.71M	-6.97M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
4.65M	4.95M	5.69M	9.55M	2.38M
	Total Assets
43.24M	38.27M	34.13M	36.73M	30.50M
	Total Debt
9.39M	7.99M	5.87M	5.32M	2.29M
	Net Debt
4.75M	3.04M	175.72K	-4.23M	-94.00K
	Total Liabilities
13.89M	13.00M	9.47M	8.88M	5.90M
	Stockholders Equity
30.15M	25.98M	25.35M	28.46M	25.21M
Cash Flow		Free Cash Flow
177.00K	-2.29M	-3.93M	-6.84M	-7.70M
	Operating Cash Flow
1.04M	-1.41M	-2.45M	-5.47M	-7.05M
	Investing Cash Flow
-837.00K	-884.90K	-1.49M	-1.37M	-651.00K
	Financing Cash Flow
-1.51M	1.10M	144.69K	14.02M	2.29M

Tissue Regenix Peers Comparison

Overall Rating

UnderperformOutperform

Sector (54)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TRX		£22.08M	―	-3.66%	―	―	―
Sector *	54 Neutral	$5.31B	3.28	-45.10%	2.80%	16.76%	0.02%
FUM		£28.23M	21.60	17.91%	―	―	―
IMM		£13.34M	―		―	―	―
AREC	59 Neutral	£16.42M	―	-137.62%	―	10.50%	-9.60%
OBD	50 Neutral	£7.83M	―	-222.16%	―	24.71%	38.28%
SAR	47 Neutral	£19.15M	―	-87.30%	―	―	71.17%

* Healthcare Sector Average

Performance Comparison

GB:TRX

Tissue Regenix

31.50

-35.00

-52.63%

GB:FUM

Futura Medical

9.60

-26.80

-73.63%

GB:IMM

ImmuPharma

2.68

0.32

13.56%

GB:OBD

Oxford BioDynamics

0.40

-7.60

-95.00%

GB:SAR

Sareum Holdings

14.25

-24.75

-63.46%

GB:AREC

Arecor Therapeutics PLC

43.50

-84.00

-65.88%

Glossary

OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.

NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.

UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.